VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Hypoxic preconditioning has protective effects against acute cerebral infarction

Hypoxic preconditioning has been shown to have protective effects against acute cerebral infarction. To investigate the protective mechanisms of hypoxic preconditioning in relation to its effects on angiogenesis, Prof. Xunming Ji and team from Xuanwu Hospital, Capital Medical University in China induced a photochemical model of cerebral infarction in an inbred line of mice (BALB/c) which were exposed to hypoxic preconditioning prior to model establishment.

24 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

Low sodium levels linked to poor targeted therapy outcomes in RCC

Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate.

11 Dec 2013

Early tumor shrinkage predicts targeted therapy efficacy in RCC

Early tumor shrinkage in patients with metastatic renal cell carcinoma following vascular endothelial growth factor-targeted therapy may herald good long-term survival, research shows.

11 Dec 2013

Certain hormones which are increased during exercise may help improve memory

Researchers at Boston University School of Medicine (BUSM) have found further evidence that exercise may be beneficial for brain health and cognition. The findings, which are currently available online in Behavioural Brain Research, suggest that certain hormones, which are increased during exercise, may help improve memory.

3 Dec 2013

Study reveals new mechanism that may block formation of new blood vessels and cancer growth

A study led by researchers at Boston University School of Medicine demonstrates a new mechanism involving a signaling protein and its receptor that may block the formation of new blood vessels and cancer growth. The findings are published in the December issue of Science Signaling.

29 Nov 2013

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion from the Japanese Ministry of Health, Labour and Welfare.

22 Nov 2013

Attractants prevent maturing nerve cells from migrating into brain

A vision is to implant nerve precursor cells in the diseased brains of patients with Parkinson's and Huntington's diseases, whereby these cells are to assume the function of the cells that have died off.

21 Nov 2013

Study shows patients at high-risk of CNV benefit from ForeseeHome device for earlier detection

The results of the Home Monitoring of the Eye (HOME) study, conducted in Age-Related Eye Disease Study 2 (AREDS2) clinical centers, executed by the EMMES Corporation and sponsored by Notal Vision Ltd. Tel Aviv, Israel, have been accepted for publication in Ophthalmology.

16 Nov 2013

Oraya presents data from INTREPID study of stereotactic radiotherapy for treatment of wet AMD

Oraya® Therapeutics, Inc. announced today that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy™ stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time today during the America Academy of Ophthalmology's (AAO) annual meeting in New Orleans.

16 Nov 2013

Researchers identify possible causes of colorectal cancer resistance to bevacizumab drug

A University of Colorado Cancer Center study published in the journal PLOS ONE shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor.

29 Oct 2013

Biomarker may predict poor pregnancy outcomes in lupus patients

Researchers at Hospital for Special Surgery in New York City have identified a biomarker that may predict poor pregnancy outcomes in lupus patients.

28 Oct 2013

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.

23 Oct 2013

VEGF News and Research

Further Reading

Hypoxic preconditioning has protective effects against acute cerebral infarction

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

New drug combination therapy effective for patients with HER2-positive breast cancer

Low sodium levels linked to poor targeted therapy outcomes in RCC

Early tumor shrinkage predicts targeted therapy efficacy in RCC

Certain hormones which are increased during exercise may help improve memory

Study reveals new mechanism that may block formation of new blood vessels and cancer growth

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Attractants prevent maturing nerve cells from migrating into brain

Study shows patients at high-risk of CNV benefit from ForeseeHome device for earlier detection

Oraya presents data from INTREPID study of stereotactic radiotherapy for treatment of wet AMD

Researchers identify possible causes of colorectal cancer resistance to bevacizumab drug

Biomarker may predict poor pregnancy outcomes in lupus patients

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Promising technique for treating eye disease proves effective in preclinical studies

REGARD VEGF receptor-2 as gastric cancer target

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Metastatic site impacts survival in targeted RCC treatment

Women with recurrent ovarian cancer survive longer after treatment with cediranib

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Latest eBooks

Industry focus eBook - The Digital Laboratory (4th edition)

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (3rd Edition)

BFEB: Advances in microplate-based assays and analysis

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation